Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor

NCT05119907 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05119907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05119907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 12, 2021
Completion date
October 31, 2026
Enrollment
53 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor